DEVELOPING KETAMINE THERAPIES
FOR LARGE-MARKET & ORPHAN INDICATIONS
Bexson Biomedical is leveraging existing technology to deliver a unique formulation of ketamine for chronic and acute pain disorders.
The opioid crisis is a Public Health Emergency in the United States.
There is desperate need for safe and potent treatments that can offer
a real alternative to opioid-based pain management.
Ketamine can offer real solutions.
Pain treatment that rivals potent opioids
Pharmacology that quiets chronic pain
Efficacy across a wide range of pain sub-types
Established safety profile
Why is this medication still unavailable in Chronic Pain Management?
New delivery systems are needed to address pharmacokinetic limitations of current ketamine preparations to allow controlled low dosing with reduced the need for monitoring.
Bexson Biomedical is striving to meet those challenges.
Bexson’s lead development project is a novel ketamine delivery system–one that includes formulation innovations tuned to a minimally invasive, wearable, subcutaneous infusion pump.
Pain management has not seen recent meaningful innovation, despite the national opioid crises. We intend to capitalize on this gap for both rare diseases and large market pain types.
In February 2019 Bexson was granted Orphan Status for ketamine in the treatment of Complex Regional Pain Syndrome, our lead indication.
In 2010, . . . as many as 1.6 million patients in the United States could become long-term opioid users each year after ambulatory surgery alone, and as many as 160,000 may develop dependence, abuse, or overdose. (Pino 2019)